- Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.
WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen Bio"), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc's previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc. The combined company's common stock and warrants will begin trading on Nasdaq Global Market ("Nasdaq") under the ticker symbols TVGN and TVGNW, respectively, beginning Thursday, February 15, 2024.
The listing with Nasdaq is expected to provide Tevogen Bio increased access to capital to accelerate the development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations. This innovative platform leverages one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, with the aim of addressing the significant unmet needs of large patient populations. ExacTcell stands in contrast with both autologous and allogeneic CAR-T platforms, which target antigens present on both healthy and diseased cells and require genetic modification of the T cells.
Dr. Ryan Saadi, Chief Executive Officer and Chairperson of Tevogen Bio Inc, and the current management team, including Kirti Desai, Chief Financial Officer, Dr. Neal Flomenberg, Chief Scientific Officer and Global R&D Lead, and Sadiq Khan, Chief Commercial Officer, will continue to lead Tevogen.
"We believe Tevogen's patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare," said Dr. Saadi. "I am pleased that, upon the closure of this transaction, investors will have the opportunity to participate in Tevogen's mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology."